References
1. Weidinger S, Novak N. Atopic dermatitis. Lancet. 2016;387:1109–22.
2. Birdi G, Cooke R, Knibb RC. Impact of atopic dermatitis on quality of
life in adults: A systematic review and meta-analysis. International
Journal of Dermatology. 2020;59:e75–91.
3. Tarhini A, Kudchadkar RR. Predictive and on-treatment monitoring
biomarkers in advanced melanoma: Moving toward personalized medicine.
Cancer Treatment Reviews [Internet]. 2018;71:8–18. Available from:
http://dx.doi.org/10.1016/j.ctrv.2018.09.005
4. Dummer R, Brase JC, Garrett J, Campbell CD, Gasal E, Squires M, et
al. Adjuvant dabrafenib plus trametinib versus placebo in patients with
resected, BRAFV600-mutant, stage III melanoma (COMBI-AD): exploratory
biomarker analyses from a randomised, phase 3 trial. The Lancet Oncology
[Internet]. 2020;21:358–72. Available from:
http://dx.doi.org/10.1016/S1470-2045(20)30062-0
5. Tampa M, Sarbu MI, Mitran MI, Mitran CI, Matei C, Georgescu SR. The
Pathophysiological Mechanisms and the Quest for Biomarkers in Psoriasis,
a Stress-Related Skin Disease. Disease Markers [Internet].
2018;2018:1–14. Available from:
http://dx.doi.org/10.1155/2018/5823684
6. Chovatiya R, Silverberg JI. The heterogeneity of atopic dermatitis.
Journal of Drugs in Dermatology [Internet]. 2022;21:172–6.
Available from: http://dx.doi.org/10.36849/JDD.6408
7. Thijs JL, Strickland I, Bruijnzeel-Koomen CAFM, Nierkens S,
Giovannone B, Csomor E, et al. Moving toward endotypes in atopic
dermatitis: Identification of patient clusters based on serum biomarker
analysis. Journal of Allergy and Clinical Immunology [Internet].
2017;140:730–7. Available from:
http://dx.doi.org/10.1016/j.jaci.2017.03.023
8. Francuzik W, Alexiou A, Worm M. Safety of dupilumab in patients with
atopic dermatitis: expert opinion. Expert Opinion on Drug Safety
[Internet]. 2021;20:997–1004. Available from:
http://dx.doi.org/10.1080/14740338.2021.1939673
9. Thaçi D, L. Simpson E, Deleuran M, Kataoka Y, Chen Z, Gadkari A, et
al. Efficacy and safety of dupilumab monotherapy in adults with
moderate-to-severe atopic dermatitis: a pooled analysis of two phase 3
randomized trials (LIBERTY AD SOLO 1 and LIBERTY AD SOLO 2). Journal of
Dermatological Science [Internet]. 2019;94:266–75. Available from:
http://dx.doi.org/10.1016/j.jdermsci.2019.02.002
10. Renert-Yuval Y, Thyssen JP, Bissonnette R, Bieber T, Kabashima K,
Hijnen D, et al. Biomarkers in atopic dermatitisa review on behalf of
the International Eczema Council. Journal of Allergy and Clinical
Immunology [Internet]. 2021;147:1174–1190.e1. Available from:
http://dx.doi.org/10.1016/j.jaci.2021.01.013
11. Reiger M, Traidl-Hoffmann C, Neumann AU. The skin microbiome as a
clinical biomarker in atopic eczema: Promises, navigation, and pitfalls.
Journal of Allergy and Clinical Immunology [Internet].
2020;145:93–6. Available from:
http://dx.doi.org/10.1016/j.jaci.2019.11.004
12. Kong HH, Oh J, Deming C, Conlan S, Grice EA, Beatson MA, et al.
Temporal shifts in the skin microbiome associated with disease flares
and treatment in children with atopic dermatitis. Genome Research
[Internet]. 2012;22:850–9. Available from:
http://dx.doi.org/10.1101/gr.131029.111
13. Francuzik W, Franke K, Schumann R, Heine G, Worm M.
Propionibacterium acnes Abundance Correlates Inversely with
Staphylococcus aureus: Data from Atopic Dermatitis Skin Microbiome. Acta
Dermato Venereologica [Internet]. 2018;98:490–5. Available from:
http://dx.doi.org/10.2340/00015555-2896
14. Francuzik W, Pažur K, Dalke M, Dölle-Bierke S, Babina M, Worm M.
Serological profiling
reveals hsa-miR-451a as a possible biomarker of anaphylaxis. JCI
insight. 2022;7:e156669.
15. Schneider CA, Rasband WS, Eliceiri KW. NIH Image to ImageJ: 25 years
of image analysis. Nature Methods [Internet]. 2012;9:671–5.
Available from: http://dx.doi.org/10.1038/nmeth.2089
16. Kuhn M. Caret: Classification and regression training
[Internet]. 2020. Available from:
https://CRAN.R-project.org/package=caret
17. Love MI, Huber W, Anders S.
Moderated estimation of
fold change and dispersion for RNA-seq data with DESeq2. Genome
Biology. 2014;15:550.
18. Nousbeck J, McAleer Ma, Hurault G, Kenny E, Harte K, Kezic S, et al.
MicroRNA analysis of childhood atopic dermatitis reveals a role for
miR-451a*. British Journal of Dermatology [Internet].
2021;184:514–23. Available from:
https://onlinelibrary.wiley.com/doi/abs/10.1111/bjd.19254
19. Iwamoto K, Moriwaki M, Miyake R, Hide M. Staphylococcus aureus in
atopic dermatitis: Strain-specific cell wall proteins and skin immunity.
Allergology International [Internet]. 2019;68:309–15. Available
from: http://dx.doi.org/10.1016/j.alit.2019.02.006
20. Hamilton JD, Harel S, Swanson BN, Brian W, Chen Z, Rice MS, et al.
Dupilumab suppresses type 2 inflammatory biomarkers across multiple
atopic, allergic diseases. Clinical & Experimental Allergy
[Internet]. 2021;51:915–31. Available from:
http://dx.doi.org/10.1111/cea.13954
21. Raap U, Goltz C, Deneka N, Bruder M, Renz H, Kapp A, et al.
Brain-derived
neurotrophic factor is increased in atopic dermatitis and modulates
eosinophil functions compared with that seen in nonatopic subjects. The
Journal of Allergy and Clinical Immunology. 2005;115:1268–75.
22. Fölster-Holst R, Papakonstantinou E, Rüdrich U, Buchner M, Pite H,
Gehring M, et al. Childhood atopic dermatitisBrain-derived neurotrophic
factor correlates with serum eosinophil cationic protein and disease
severity. Allergy [Internet]. 2016;71:1062–5. Available from:
https://onlinelibrary.wiley.com/doi/abs/10.1111/all.12916
23. Wechsler ME, Klion AD, Paggiaro P, Nair P, Staumont-Salle D, Radwan
A, et al. Effect of Dupilumab on Blood Eosinophil Counts in Patients
With Asthma, Chronic Rhinosinusitis With Nasal Polyps, Atopic
Dermatitis, or Eosinophilic Esophagitis. The Journal of Allergy and
Clinical Immunology: In Practice [Internet]. 2022;10:2695–709.
Available from: http://dx.doi.org/10.1016/j.jaip.2022.05.019
24. Morita H, Kitano Y, Kawasaki N.
Elevation of
serum-soluble E-selectin in atopic dermatitis. Journal of
Dermatological Science. 1995;10:145–50.
25. Chong BF, Murphy JE, Kupper TS, Fuhlbrigge RC.
E-selectin, thymus-
and activation-regulated chemokine/CCL17, and intercellular adhesion
molecule-1 are constitutively coexpressed in dermal microvessels: a
foundation for a cutaneous immunosurveillance system. Journal of
Immunology (Baltimore, Md: 1950). 2004;172:1575–81.
26. Khattri S, Shemer A, Rozenblit M, Dhingra N, Czarnowicki T, Finney
R, et al. Cyclosporine
in patients with atopic dermatitis modulates activated inflammatory
pathways and reverses epidermal pathology. The Journal of Allergy and
Clinical Immunology. 2014;133:1626–34.
27. Wollenberg A, Howell MD, Guttman-Yassky E, Silverberg JI, Kell C,
Ranade K, et al. Treatment of atopic dermatitis with tralokinumab, an
antiIL-13 mAb. Journal of Allergy and Clinical Immunology
[Internet]. 2019;143:135–41. Available from:
https://www.sciencedirect.com/science/article/pii/S0091674918308509
28. Brunner PM, Pavel AB, Khattri S, Leonard A, Malik K, Rose S, et al.
Baseline IL-22 expression in patients with atopic dermatitis stratifies
tissue responses to fezakinumab. Journal of Allergy and Clinical
Immunology [Internet]. 2019;143:142–54. Available from:
https://www.jacionline.org/article/S0091-6749(18)31141-2/fulltext
29. Kakinuma T, Nakamura K, Wakugawa M, Mitsui H, Tada Y, Saeki H, et
al. Thymus and
activation-regulated chemokine in atopic dermatitis: Serum thymus and
activation-regulated chemokine level is closely related with disease
activity. The Journal of Allergy and Clinical Immunology.
2001;107:535–41.
30. Nakazato J, Kishida M, Kuroiwa R, Fujiwara J, Shimoda M, Shinomiya
N. Serum levels
of Th2 chemokines, CCL17, CCL22, and CCL27, were the important markers
of severity in infantile atopic dermatitis. Pediatric Allergy and
Immunology: Official Publication of the European Society of Pediatric
Allergy and Immunology. 2008;19:605–13.
31. Koizumi M, Kuzume K, Ishida Y, Midoro-Horiuti T. Serum thymus and
activation-regulated chemokine (TARC) levels correlate with atopic
dermatitis disease severity in patients < 6 months. Allergy
and Asthma Proceedings [Internet]. 2022;43:461–7. Available from:
http://dx.doi.org/10.2500/aap.2022.43.220034
32. Silverberg JI, Margolis DJ, Boguniewicz M, Fonacier L, Grayson MH,
Ong PY, et al. Validation of five patient-reported outcomes for atopic
dermatitis severity in adults. British Journal of Dermatology
[Internet]. 2019; Available from:
http://dx.doi.org/10.1111/bjd.18002
33. Beck LA, Thaçi D, Hamilton JD, Graham NM, Bieber T, Rocklin R, et
al. Dupilumab treatment in
adults with moderate-to-severe atopic dermatitis. The New England
Journal of Medicine. 2014;371:130–9.
34. Hamilton JD, Suárez-Fariñas M, Dhingra N, Cardinale I, Li X, Kostic
A, et al. Dupilumab
improves the molecular signature in skin of patients with
moderate-to-severe atopic dermatitis. The Journal of Allergy and
Clinical Immunology. 2014;134:1293–300.
35. Simpson E, Eckert L, Gadkari A, Mallya UG, Yang M, Nelson L, et al.
Validation of the Atopic Dermatitis Control Tool (ADCT©) using a
longitudinal survey of biologic-treated patients with atopic dermatitis.
BMC Dermatology [Internet]. 2019;19. Available from:
http://dx.doi.org/10.1186/s12895-019-0095-3
36. Chopra R, Silverberg JI. Assessing the severity of atopic dermatitis
in clinical trials and practice. Clinics in Dermatology [Internet].
2018;36:606–15. Available from:
http://dx.doi.org/10.1016/j.clindermatol.2018.05.012
37. Ungar B, Garcet S, Gonzalez J, Dhingra N, Correa da Rosa J, Shemer
A, et al. An Integrated
Model of Atopic Dermatitis Biomarkers Highlights the Systemic Nature of
the Disease. The Journal of Investigative Dermatology.
2017;137:603–13.
38. Nakahara T, Izuhara K, Onozuka D, Saeki H, Nunomura S, Takenaka M,
et al. Exploring biomarkers to predict clinical improvement of atopic
dermatitis in patients treated with dupilumab ( B-PAD study). Clinical
& Experimental Allergy [Internet]. 2022; Available from:
http://dx.doi.org/10.1111/cea.14267
39. miRNA expression profiles of the perilesional skin of atopic
dermatitis and psoriasis patients are highly similar |
scientific reports [Internet]. Available from:
https://www.nature.com/articles/s41598-022-27235-2
40. Callewaert C, Nakatsuji T, Knight R, Kosciolek T, Vrbanac A, Kotol
P, et al. IL-4Rα Blockade by Dupilumab Decreases Staphylococcus aureus
Colonization and Increases Microbial Diversity in Atopic Dermatitis.
Journal of Investigative Dermatology [Internet].
2020;140:191–202.e7. Available from:
http://dx.doi.org/10.1016/j.jid.2019.05.024
41. Martin M. Cutadapt removes adapter sequences from high-throughput
sequencing reads. EMBnet J [Internet]. 2011;17:10. Available from:
https://doi.org/10.14806/ej.17.1.200
42. Griffiths-Jones S, Saini HK, Dongen S van, Enright AJ. miRBase:
Tools for microRNA genomics. Nucleic Acids Research [Internet].
2007;36:D154–8. Available from:
https://doi.org/10.1093/nar/gkm952
43. Friedländer MR, Mackowiak SD, Li N, Chen W, Rajewsky N. miRDeep2
accurately identifies known and hundreds of novel microRNA genes in
seven animal clades. Nucleic Acids Research [Internet].
2011;40:37–52. Available from: https://doi.org/10.1093/nar/gkr688
44. Andrews S. FastQC: A quality control tool for high throughput
sequence data. Babraham bioinformatics, Babraham Institute, Cambridge,
United Kingdom. 2010;
45. Sayols S, Scherzinger D, Klein H. dupRadar: A bioconductor package
for the assessment of PCR artifacts in RNA-seq data. BMC Bioinformatics.
2016;17.
46. R Core Team. R: A language and environment for statistical computing
[Internet]. Vienna, Austria: R Foundation for Statistical Computing;
2020. Available from:
https://www.R-project.org/
47. Stephens M. False discovery rates: A new deal. Biostatistics
[Internet]. 2016;275–94. Available from:
https://doi.org/10.1093/biostatistics/kxw041
48. Ignatiadis N, Klaus B, Zaugg JB, Huber W. Data-driven hypothesis
weighting increases detection power in genome-scale multiple testing.
Nature Methods [Internet]. 2016;13:577–80. Available from:
https://doi.org/10.1038/nmeth.3885
49. Galili, Tal, O’Callaghan, Alan, Sidi, Jonathan, et al. Heatmaply: An
r package for creating interactive cluster heatmaps for online
publishing. Bioinformatics. 2017;34:1600–2.